The effect of gender on the 50% effective dose of remimazolam for achieving loss of consciousness

The effect of gender on the ED50 of remimazolam for loss of consciousness in adult patients co-administered with remifentanil infusion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007951

Enrollment

Registered

2022-12-02

Start date

2022-12-05

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Others : Group divided only by gender. Remifentanil is started by target controlled infusion and in both group, remimazolam starting dose is 0.15 mg/kg. Remimazolam is given once by IV pathway a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients aged 19-60 years with ASA score 1 or 2 scheduled for general anesthesia

Exclusion criteria

Exclusion criteria: BMI > 30 kg/m2 History of allergies to benzodiazepines History of allergies to opioids Patients unable to response on verbal command Use of opioids, alcohol, benzodiazeplines and over-the-counter sleep aids

Design outcomes

Primary

Measure	Time frame
Gender difference in 50% effective dose of remimazolam for achieving loss of consciousness with remifentanil target-controlled infusion	—

Secondary

Measure	Time frame
ED50, ED95 acheived by isotonic regression, vital signs (blood pressure, heart rate, oxygen saturation), UniCon (ADMS™, Anaesthetic Depth Monitor for Sedation) index, loss of consciousness time	—

Countries

Korea, Republic of

Contacts

Public ContactJu Yeon Oh

Ajou University Hospital

itisamy@hanmail.net+82-31-219-4919

Outcome results